O Dear knocked on the wrong door14 Dec 2020 13:27
AstraZeneca’s $39 Billion Alexion Deal Draws Investor Questions
“If you don’t have cash, don’t buy a large company unless it is a once-in-a-lifetime opportunity and has strong strategic merits,” Manns said. “You can hardly call this deal a once-in-a-lifetime opportunity, and the strategic merits are weak.”